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Abstract
Aims/hypothesis Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular
disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a
subset of participants from the SUSTAIN 8 Phase IIIB, randomised double-blind trial who underwent whole-body dual-energy
x-ray absorptiometry (DXA) scanning.
Methods Adults (age ≥18 years) with type 2 diabetes, HbA1c 53–91mmol/mol (7.0–10.5%), on a stable daily dose of metformin
(≥1500 mg or maximum tolerated dose) and with an eGFR ≥60 ml min−1 [1.73 m]−2 were randomised 1:1 to semaglutide 1.0 mg
once weekly and canagliflozin placebo once daily, or canagliflozin 300 mg once daily and semaglutide placebo once weekly.
Body composition was assessed using whole-body DXA scans. The study participants and investigator remained blinded
throughout the trial, and quality of DXA scans was evaluated in a blinded manner. Change from baseline to week 52 in total
fat mass (kg) was the confirmatory efficacy endpoint.
Results A subset of 178 participants (semaglutide, n = 88; canagliflozin, n= 90) underwent DXA scanning at screening and were
randomised into the substudy. Of these, 114 (semaglutide, n = 53; canagliflozin, n = 61) participants had observed end-of-treatment
data included in the confirmatory efficacy analysis. Of the 178 participants in the substudy, numerical improvements in body
composition (including fat mass, lean mass and visceral fat mass) were observed after 52 weeks with both treatments. Total fat mass
(baseline 33.2 kg) was reduced by 3.4 kg and 2.6 kgwith semaglutide and canagliflozin, respectively (estimated treatment difference: –
0.79 [95% CI −2.10, 0.51]). Although total lean mass (baseline 51.3 kg) was also reduced by 2.3 kg and 1.5 kg with semaglutide and
canagliflozin, respectively (estimated treatment difference:−0.78 [−1.61, 0.04]), the proportion of leanmass (baseline 59.4%) increased
by 1.2%- and 1.1%-point, respectively (estimated treatment difference 0.14 [−0.89, 1.17]). Changes in visceral fat mass and overall
changes in body composition (assessed by the fat to lean mass ratio) were comparable between the two treatment groups.
Conclusions/interpretation In individuals with uncontrolled type 2 diabetes on stable-dose metformin therapy, the changes in
body composition with semaglutide and canagliflozin were not significantly different. Although numerical improvements in
body composition were observed following treatment in both treatment arms, the specific impact of both treatments on body
composition in the absence of a placebo arm is speculative at this stage.
Trial registration ClinicalTrials.gov NCT03136484.
Funding This trial was supported by Novo Nordisk A/S, Denmark.
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Abbreviations
DXA Dual-energy x-ray absorptiometry
ETD Estimated treatment difference
GLP-1RA Glucagon-like peptide-1 receptor agonist
SGLT-2i Sodium–glucose co-transporter-2 inhibitor
SUSTAIN Semaglutide Unabated Sustainability in
Treatment of Type 2 Diabetes
Introduction
The association between obesity and type 2 diabetes is well
established [1, 2]. Intra-abdominal or visceral obesity in particular
is associatedwith insulin resistance [3, 4] and an increased risk for
developing cardiovascular disease [4, 5]. In addition to providing
recommendations for achieving glycaemic control, current type 2
diabetes guidelines emphasise the importance of weight loss
through lifestyle changes, surgical interventions or medications
[6, 7]. While some conventional glucose-lowering medications
contribute toweight gain [2], newer agents – including those from
the glucagon-like peptide-1 receptor agonist (GLP-1RA) and
sodium–glucose co-transporter-2 inhibitor (SGLT-2i) classes –
have favourable effects on body weight [2]. This is an important
feature, because weight gain can lead to non-compliance with
therapy [8].
Semaglutide is a GLP-1RA approved for the subcutaneous,
once-weekly treatment of type 2 diabetes [9, 10]. The efficacy and
safety of once-weekly semaglutide have been established in the
SUSTAIN (Semaglutide Unabated Sustainability in Treatment of
Type 2Diabetes) clinical trial programme across the continuumof
care in individuals with type 2 diabetes vs placebo and a range of
comparators (SUSTAIN 1–5 and 7–10) [11–19] and in a cardio-
vascular outcomes trial (SUSTAIN 6) [20]. Canagliflozin is an
SGLT-2i approved for the oral, once-daily treatment of type 2
diabetes [21]. The efficacy and safety of canagliflozin 100 mg
and 300 mg have been demonstrated in an extensive clinical
development programme that included cardiovascular and renal
outcomes trials (CANVAS, CANVAS-R and CREDENCE) [22,
23]. Both semaglutide and canagliflozin are associated with
substantial reductions in body weight. Across the SUSTAIN 1–
10 trials, semaglutide has demonstrated significantly greater
weight loss vs all comparators, with absolute change in body
weight ranging from −3.8 to −6.5 kg with semaglutide 1.0 mg
[11–20]. Canagliflozin has consistently demonstrated weight
reductions of 2.5 to 4.7 kg in clinical trials [24].
Recently, a Phase IIIB randomised double-blind trial
(SUSTAIN 8) compared the effects of once-weekly
semaglutide 1.0 mg vs once-daily canagliflozin 300 mg
on glycaemic control and weight management in partici-
pants with uncontrolled type 2 diabetes on a background
of metformin therapy [17]. Treatment with semaglutide
resulted in a mean change in HbA1c from baseline to
week 52 of −16.2 mmol/mol (−1.5%-point) compared
with −10.4 mmol/mol (−1.0%-point) for canagliflozin
(p < 0.0001), and a weight loss of −5.3 kg vs −4.2 kg,
respectively (p = 0.003).
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The magnitude of weight loss demonstrated in the
SUSTAIN 8 trial would be expected to result in positive
changes in body composition; however, as with any glucose-
lowering agent, it is important to evaluate whether this weight
loss has an adverse impact on the ratio of fat to lean mass.
To date, whether the effects on weight loss associated with
the GLP-1RA semaglutide, and the SGLT-2i canagliflozin, are
comparable in terms of total, lean and visceral fat have not yet
been evaluated. This study compared body composition
components in a subset of participants from SUSTAIN 8
who received semaglutide 1.0 mg or canagliflozin 300 mg
using whole-body dual-energy x-ray absorptiometry (DXA).
Methods
SUSTAIN 8 study design
Trial design and participants The trial design for SUSTAIN 8
(ClinicalTrials.gov registration no. NCT03136484) has been
described previously [17]. Briefly, SUSTAIN 8 was a 52-
week, Phase IIIB randomised double-blind, double-dummy,
parallel-group trial of once-weekly semaglutide 1.0 mg vs
once-daily canagliflozin 300 mg in 788 adults with type 2
diabetes on stable treatment with metformin. The trial was
conducted at 111 centres in 11 countries. Adults (age
≥18 years) with uncontrolled type 2 diabetes, HbA1c levels
of 53–91 mmol/mol (7.0–10.5% [inclusive]) on a stable daily
dose of metformin (≥1500mg or maximum tolerated dose) for
at least 90 days prior to screening and an eGFR ≥60 ml min−1
[1.73 m]−2 were eligible. Individuals with a history or pres-
ence of pancreatitis (acute or chronic), history of diabetic
ketoacidosis, myocardial infarction, stroke, hospitalisation
for unstable angina or transient ischaemic attack within
180 days prior to screening, and New York Heart
Association class IV heart failure were excluded.
Randomisation and treatment Participants were randomised
in a 1:1 manner to receive either once-weekly semaglutide
1.0 mg subcutaneous injections and once-daily canagliflozin
placebo oral tablets, or once-daily canagliflozin 300 mg oral
tablets and once-weekly subcutaneous semaglutide placebo.
Randomisation was stratified according to participation in the
substudy (yes/no) to ensure balanced treatment allocation.
Dosing for semaglutide began at 0.25 mg and doubled every
4 weeks until the maintenance dose of 1.0 mg was achieved at
8 weeks. Participants randomised to canagliflozin received
100 mg for 8 weeks, followed by an increase to the mainte-
nance dose of 300 mg. The only background medication
permitted was metformin (≥1500 mg or maximum tolerated
dose). Participants continued on their pre-trial dose through-
out the treatment period unless rescue medication was
required. After a treatment period of 52 weeks, participants
entered a 5-week follow-up period.
Outcomes The primary and confirmatory secondary endpoints
were change from baseline toweek 52 inHbA1c (%-point) and
body weight (kg), respectively.
Ethics and consent SUSTAIN 8 was conducted in compliance
with the International Conference on Harmonisation Good
Clinical Practice guidelines [25] and the Declaration of
Helsinki [26]. The trial protocol was approved by the institu-
tional review board and ethics committee at each participating
centre, and participants provided written informed consent
before trial-related activities commenced.
DXA substudy
A planned subset of participants from the overall SUSTAIN 8
population received a DXAwhole-body scan at baseline and
were randomised for inclusion in the body composition
substudy if the imaging laboratory deemed the quality of the
scan to be acceptable.
Assessments and outcomes The process of DXA scan image
acquisition, transfer, central analysis, reporting of results and
arching followed the charter prepared by one imaging labora-
tory (PAREXEL Informatics Medical Imaging, Waltham,
MA, USA) where scans were analysed. GE Lunar iDXA
(GE Healthcare, Madison, WI, USA) and the Hologic
Discovery DXA system (Hologic, Marlborough, MA, USA)
were used with Prodigy and APEX software, respectively.
Each participant received one scan 5 days after the screening
(visit 1) and a second, final scan 5 days after the end-of-
treatment visit (planned study end or premature treatment
discontinuation). The quality of the DXA scans was evaluated
by the same imaging laboratory in a blinded manner.
Change from baseline to week 52 in total fat mass (kg) was
the confirmatory efficacy endpoint in the DXA substudy.
Changes from baseline to week 52 in total fat mass (%-point),
total lean mass (kg and %-point), visceral fat mass (kg and %-
point) and ratio of total fat mass to total leanmass (muscle mass
in this study) were additional efficacy endpoints. A comparison
of change in body weight within the substudy vs the primary
study was performed post hoc in order to confirm that weight
loss in individuals undergoing a DXA scan in the substudy was
representative of the weight loss in the primary study.
Statistical analyses The primary estimand was defined as the
treatment difference between semaglutide and canagliflozin at
week 52 for all randomised participants if all participants
completed treatment and did not start rescue medication.
The primary estimandwas used to estimate the expected bene-
fit from the initiation and continuation of semaglutide
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compared with canagliflozin, drawing inferences only from
data collected before discontinuation of trial product or initia-
tion of rescue medication. The estimand was based on the full
analysis set of all randomised participants using post-baseline
measurements up to and including week 52 from the ‘on-
treatment without rescue medication’ observation period to
support an efficacy evaluation. The analysis of all endpoints
in the substudy was based on the subset of full analysis set
participants who participated in the substudy (DXA analysis
set); however, participants had only two DXA scans each, and
not all of these were performed within the ‘on-treatment with-
out rescuemedication’ observation period (used for the confir-
matory analysis). In individuals for whom DXA data were
collected outside of this period, only baseline data were
included in the analysis, and the corresponding end-of-
treatment data were multiple imputed, as described below.
An ANCOVA with treatment and region as categorical
effects and baseline measurements as a covariate was used
to analyse values at week 52, and change from baseline esti-
mates were adjusted according to the pooled baseline value to
allow for comparison between treatment arms. Before analy-
sis, missing data were imputed using observed data from
participants within the same treatment group, using a regres-
sion model including region as categorical effect and baseline
value as covariate. Rubin’s rules were used to combine the
analysis results to draw inference [27]. Regions were defined
as North America (USA and Canada); Region Europe (UK,
Ireland and Sweden); or International Operations (Lebanon,
Malaysia, Argentina, Mexico, Brazil and India).
As a confirmatory endpoint, change in total fat mass (kg)
was tested for superiority of semaglutide 1.0 mg vs
canagliflozin 300 mg. The overall type I error for the confir-
matory hypotheses in SUSTAIN 8 and the substudy were
controlled at a 5% level (two-sided) using a closed testing
procedure (Fig. 1) [28]. Assuming a treatment difference of
1.8 kg and SD of 3.5 kg, it was estimated that 174 participants
(87 per arm) would provide a 92%marginal power to establish
a significant difference, resulting in 91% power for
confirming superiority in the testing strategy for total fat mass
loss (kg) at week 52.
Sensitivity analyses to evaluate the robustness of the
conclusions from the confirmatory analysis (change in total
fat mass [kg]) included a pre-specified in-trial analysis using
all post-baseline measurements up to and including week 52
from the in-trial observation period, in which participants
were considered to be in the trial after randomisation regard-
less of discontinuation of trial product or initiation of rescue
medication. Scans that did not meet the criteria for inclusion in
the confirmatory analysis (performed >7 days after last dose
of trial product and thus considered out-of-window, or taken
after initiation of rescue medication) were included in the in-
trial supplementary analysis. Data from missing scans were
multiple imputed.
In post hoc analyses, possible correlations between fat loss
and changes in bodyweight, HbA1c and BPwere investigated.
Correlations were calculated for each of the 500 complete
multiple imputed datasets for bodyweight, HbA1c and systolic
and diastolic BP and combined using Rubin’s rules [27].
Results
Between 15 March 2017 and 16 November 2018, 788 indi-
viduals were randomised to receive semaglutide 1.0 mg or
canagliflozin 300 mg (each n = 394). A subset of 178 partic-
ipants (semaglutide, n = 88; canagliflozin, n = 90) underwent
DXA scanning at screening and were also randomised into the
SUSTAIN 8 substudy. Of these, 177 (99.4%) participants
(semaglutide, n = 87; canagliflozin, n = 90) were exposed to
treatment. In total, 25 (14.0%) participants discontinued treat-
ment prematurely, primarily because of adverse events (n = 8
[4.5%]). Overall, 165 of 178 participants (92.7%) had a post-
baseline DXA scan available (Table 1; Fig. 2). Of these, data
on 114 (64%: semaglutide, n = 53 [60.2%]; canagliflozin, n =
61 [67.8%]) were within the on-treatment without rescue
medication period and used in the confirmatory efficacy anal-
ysis (Table 1; Fig. 2). The remaining post-baseline DXA scan
results were excluded from the confirmatory analysis because
scans at discontinuation were performed >7 days after the last
dose of trial product (i.e. out-of-window; n = 38) or partici-
pants were on rescue medication at the time of the scan (n =
13). The pre-specified in-trial analysis used all post-baseline
measurements up to and including week 52 from the in-trial
observation period, i.e. all 165 available post-baseline scans
(including out-of-window scans and scans of participants on
rescue medication).
Baseline characteristics
Baseline characteristics were comparable between treatment
arms (Table 1). Participants had an overall mean (SD) baseline
HbA1c value of 68.0 mmol/mol (11.5) [8.4% (1.0)] and body
weight of 88.3 kg (18.2). Overall mean (SD) baseline body
composition values were 33.2 kg (11.0) and 37.6% (7.8) for
total fat mass, 51.3 kg (10.4) and 59.4% (7.5) for total lean
mass, and 1.5 kg (0.8) (representing 43.9% [15.7] of abdom-
inal fat) for visceral fat mass. The overall mean (SD) baseline
total fat mass to total lean mass ratio was 0.7 (0.2).
Change in total fat mass
Numerical reductions in fat mass (kg and %-point) were
observed with both treatments. Estimated reductions were
numerically greater for semaglutide vs canagliflozin, but the
differences were not statistically significant (Fig. 3a, b). Total
fat mass (SE) was reduced with semaglutide and canagliflozin
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from an overall baseline of 33.2 kg: 3.4 kg (0.51) vs 2.6 kg
(0.45), respectively (Fig. 3a), with an estimated treatment
difference (ETD; 95% CI) of −0.79 (−2.10, 0.51). The supple-
mentary in-trial analysis of all available data demonstrated
similar, non-significant results for total fat mass with reduc-
tions of 3.0 kg (0.37) and 2.3 kg (0.36) for semaglutide and
canagliflozin, respectively (ETD –0.71 [95%CI –1.72, 0.31]).
The proportion of total fat mass (SE) was reduced from an
overall baseline of 37.6% by 1.4%-point (0.39) and 1.2%-
point (0.35) with semaglutide and canagliflozin, respectively
(ETD –0.21 [95% CI –1.26, 0.84]) (Fig. 3b). Cumulative
changes in total fat mass were comparable between
semaglutide and canagliflozin; over 52 weeks, approximately
80% of participants experienced reduced total fat mass with
both treatments (Fig. 3h).
Post hoc correlation coefficient analysis A moderate correla-
tion was observed between change in total fat mass and
change in body weight between baseline and week 52 for
semaglutide (r = 0.61 [95% CI 0.40, 0.76]) and canagliflozin
(r = 0.54 [0.32, 0.70]) (Fig. 4a). There were no correlations
between change in total fat mass and change in HbA1c, systol-
ic BP or diastolic BP over the same period with either
semaglutide or canagliflozin (r = 0.01–0.20) (Fig. 4b–d).
Change in total lean mass
Total lean mass (SE) was reduced from an overall baseline of
51.3 kg by 2.3 kg (0.30) vs 1.5 kg (0.28) in the semaglutide
and canagliflozin treatment groups, respectively (ETD –0.78
[95% CI –1.61, 0.04]) (Fig. 3c). In contrast, lean mass as a
proportion of the whole (SE) increased from an overall base-
line of 59.4% by 1.2%-point (0.39) with semaglutide vs 1.1%-
point (0.34) with canagliflozin (ETD 0.14 [−0.89, 1.17])
(Fig. 3d).
Change in visceral fat mass
The decreases in visceral fat mass (SE) were 0.2 kg (0.05) and
0.1 kg (0.04) with semaglutide and canagliflozin, respectively
(ETD –0.07 [95% CI –0.20, 0.06]) (Fig. 3e). The percentage
of visceral fat mass (SE) decreased from an overall baseline
mean of 43.9% by 0.9%-point (0.94) with semaglutide vs an
increase of 0.4%-point (0.69) with canagliflozin (ETD –1.38
[−3.65, 0.88]) (Fig. 3f).
Ratio between total fat mass and total lean mass
Body composition changes, as assessed by the fat to lean mass
ratio (SE), were favourable for both treatment groups: −0.04
(0.01) and −0.03 (0.01) with semaglutide and canagliflozin,
respectively (ETD –0.01 [95% CI –0.04, 0.02]) (Fig. 3g).
Change in body weight
In a post hoc calculation of the substudy cohort (n = 178),
which served to illustrate consistency between weight loss in
participants undergoing a DXA scan in the substudy and in the
primary study, reduction in total fat plus lean mass was 5.7 kg
with semaglutide vs 4.1 kg with canagliflozin in the substudy,
suggesting a weight-loss pattern similar to that observed
between treatments in the whole SUSTAIN 8 population
(Table 2). Moreover, the distribution of body weight loss
was similar in the SUSTAIN 8 substudy compared with the
main SUSTAIN 8 trial in participants receiving both
semaglutide and canagliflozin (Fig. 5a, b, respectively).
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Fig. 1 Graphical illustration of the closed testing procedure. The overall
significance level of α = 0.05 (two-sided) is initially allocated to the
HbA1c non-inferiority test. The local significance level (αlocal) will be
reallocated if a hypothesis is confirmed according to the weight given
by the directed edges between nodes (hypotheses). The total fat-mass
superiority test will receive the overall significance of α = 0.05 (two-
sided) if, and only if, both HbA1c and body weight superiority are
confirmed at their respective local significance levels
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Discussion
In the SUSTAIN 8 substudy, numerical reductions in absolute
and proportion of total fat mass were observed for treatment
with both semaglutide 1.0 mg and canagliflozin 300 mg.
Although fat loss was numerically greater with semaglutide
vs canagliflozin after 52 weeks of treatment, the difference
was not statistically significant. Overall, 36% of participants
were missing DXA scans for the end-of-treatment confirma-
tory analysis, mainly because scans were taken out-of-window
(>7 days after the last dose of trial product). However, the
supplementary in-trial analysis of all available scans demon-
strated similar results, supporting the robustness of the conclu-
sion for this endpoint. Numerical reductions were observed in
both treatment groups in absolute lean mass (kg), although an
increase in the proportion of total lean mass (%-point) was
observed. However, the change in ratio between total fat mass
and total lean mass was minimal in both treatment groups, and
was not significantly different between groups. A marginal
decrease in absolute visceral fat mass was observed with both
Table 1 Body composition
substudy participant disposition
and baseline characteristics
Variable Semaglutide
1.0 mg (n = 88)
Canagliflozin
300 mg (n = 90)
Total (n = 178)
Participant disposition, n (%)
Randomised, DXA 88 (100) 90 (100) 178 (100)
Exposed 87 (98.9) 90 (100) 177 (99.4)
Observed EOT scan in in-trial analysisa 82 (93.2) 83 (92.2) 165 (92.7)
Observed EOT scan in confirmatory analysisb 53 (60.2) 61 (67.8) 114 (64.0)
Treatment completersc 76 (86.4) 76 (84.4) 152 (85.4)
Without rescue medication 63 (71.6) 69 (76.7) 132 (74.2)
Premature treatment discontinuationd 11 (12.5) 14 (15.6) 25 (14.0)
Adverse events 6 (6.8) 2 (2.2) 8 (4.5)
Lost to follow-up 1 (1.1) 2 (2.2) 3 (1.7)
Other 4 (4.5) 10 (11.1) 14 (7.9)
Trial completerse 80 (90.9) 81 (90.0) 161 (90.4)
Demographics and baseline characteristics, mean (SD)
Age, years 57.8 (9.9) 58.6 (10.1) 58.2 (10.0)
HbA1c, mmol/mol 69.4 (11.9) 66.7 (10.9) 68.0 (11.5)
HbA1c, % 8.5 (1.1) 8.3 (1.0) 8.4 (1.0)
Diabetes duration, years 8.8 (5.8) 8.5 (5.2) 8.7 (5.5)
Body weight, kg 89.0 (18.2) 87.6 (18.2) 88.3 (18.2)
BMI, kg/m2 32.6 (6.4) 32.3 (5.5) 32.4 (6.0)
Waist circumference, cm 104.0 (13.5) 105.9 (13.1) 105.0 (13.3)
Total fat mass,
kg
%
33.9 (11.9)
38.0 (8.4)
32.5 (10.0)
37.3 (7.3)
33.2 (11.0)
37.6 (7.8)
Total lean mass,
kg
%
51.3 (10.1)
59.1 (8.0)
51.3 (10.7)
59.7 (6.9)
51.3 (10.4)
59.4 (7.5)
Visceral fat mass,
kg
%
1.5 (0.8)
43.7 (16.2)
1.5 (0.8)
44.0 (15.3)
1.5 (0.8)
43.9 (15.7)
Total fat mass:total lean mass ratio 0.67 (0.23) 0.65 (0.20) 0.66 (0.22)
The baseline value is defined as the latest pre-dosing value
a Participants with end-of-treatment data included in the pre-specified supplementary analysis
b Participants with end-of-treatment data included in the pre-specified confirmatory analyses
c Participants who completed treatment according to the end-of-treatment form
d Includes only exposed participants
e Participants who completed the trial according to the end-of-trial form
EOT, end-of-treatment (planned or premature)
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treatments, whereas the proportion of visceral fat decreased
slightly with semaglutide and increased slightly with
canagliflozin, although differences between treatment arms
were not significant. Importantly, in this substudy, there was
no evidence of deleterious body composition changes, such as
reductions in proportion of total lean mass; although the
specific impact of both treatments on body composition in
the absence of a placebo arm is speculative at this stage.
DXA, a two-compartment method of body composition
analysis that separates body components into fat mass and
fat-free mass, is one of the most popular and widely used
non-invasive techniques for estimating whole-body and
regional body composition [29]. When used in relation to
body composition, the term ‘lean mass’ usually refers to
muscle mass; however, lean mass comprises the combined
weight of internal organs, muscle, connective tissue and water.
It is important to consider the influence of these non-muscle
components in DXA measurements of lean mass, and partic-
ularly the inability of DXA to calculate variable amounts of
water [29], making it difficult to distinguish between loss of
muscle and reduction in extracellular volume.
The link between obesity and type 2 diabetes is well known
[1, 2]. Abdominal obesity is a key factor in the development of
diabetes and cardiovascular disease [30] and is a risk factor for
several chronic diseases with cardiometabolic homeostasis
[31]. Recent studies showing reduction in visceral fat in
normal-weight [31] and overweight individuals [32] may have
implications with regard to improving cardiometabolic profile.
Although many conventional glucose-lowering therapies may
contribute to weight gain, treatment with GLP-1RAs and
SGLT-2is has been associated with clinically meaningful
weight loss [2]. In SUSTAIN 8, treatment with semaglutide
and canagliflozin resulted in substantial weight loss of
−5.3 kg and −4.2 kg, respectively (ETD –1.06 [95% CI –
1.76, −0.36]; p = 0.003 favouring semaglutide), with more
participants in the semaglutide arm achieving weight loss
≥10% than those in the canagliflozin arm (22.3% vs 8.9%;
OR 2.99 [95% CI 1.89, 4.75]; p < 0.0001). A post hoc calcula-
tion of reduction in overall mass (fat mass plus lean body mass)
in the DXA substudy indicated reductions of 5.7 kg vs 4.1 kg
for semaglutide and canagliflozin, respectively. The distribution
of body weight loss in participants in the SUSTAIN 8 substudy
receiving semaglutide and canagliflozin was similar compared
with all participants in the primary SUSTAIN 8 trial.
The magnitude of weight loss may have implications for
the effect of treatment on lean muscle mass. Regular diet-
Screened (N=1212) 
Screen failures (n=372)
a 
did not meet inclusion criteria (n=298)
met exclusion criteria (n=88) 
other (n=3)  
Not assigned (n=52)
b 
SUSTAIN 8 trial (N=788) 
semaglutide (n=394) 
canagliflozin (n=394) 
SUSTAIN 8 substudy (n=178)
c
Semaglutide 1.0 mg (n=88)
exposed (n=87) 
not exposed (n=1)
Discontinued treatment (n=11)
adverse events (n=6) 
lost to follow-up (n=1) 
other (n=4) 
Completed trial (n=80) 
Completed treatment (n=76) 
Required rescue medication (n=13) 
Contributing with post-baseline data to the confirmatory analysis (n=53)
d
Contributing with post-baseline data to the in-trial analysis (n=82)
e
Completed trial (n=81) 
Completed treatment (n=76) 
Required rescue medication (n=7) 
Contributing with post-baseline data to the confirmatory analysis (n=61)
d
Contributing with post-baseline data to the in-trial analysis (n=83)
e
Canagliflozin 300 mg (n=90) 
exposed (n=90) 
not exposed (n=0) 
Discontinued treatment (n=14)
adverse events (n=2) 
lost to follow-up (n=2) 
other (n=10) 
Randomised (N=788) 
Fig. 2 Participant disposition. aParticipants could meet more than one
exclusion criterion. b‘Not assigned’ includes individuals who withdrew
consent before randomisation. cParticipants in the substudy were a subset
of the overall SUSTAIN 8 trial population. dIn participants for whom data
were outside the relevant observation period, only baseline participant
data were included in the analysis, and the corresponding end-of-treat-
ment data were multiple imputed. eThe in-trial analysis included all avail-
able post-baseline data. Missing data were multiple imputed
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induced weight loss is associated with corresponding changes
in both body fat and fat-free mass, including muscle [33]. In
individuals with type 2 diabetes, it is preferable to reduce fat
without significant loss of lean mass [32], although this can
occur during weight loss in those who are obese [34]. Because
skeletal muscle is the major site of postprandial glucose
uptake [35], a decrease in lean mass may be associated with
impaired glucose metabolism in individuals with type 2 diabe-
tes. However, this is a complex process for which there are
various contributing factors. A recent trial examining the
effect of the SGLT-2i ipragliflozin in Japanese people with
obesity revealed similar mean reductions of fat mass and total
lean mass of 1.8 kg and 1.7 kg, respectively, including a small
but significant 0.6 kg loss in appendicular lean mass (a good
marker of skeletal muscle mass), suggesting that SGLT-2is
may induce catabolism of both body fat and muscle secondary
to glycosuria [36]. However, the use of DXA for the estima-
tion of changes in body composition in SGLT-2i trials has
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Fig. 3 Body composition
outcomes after 52 weeks of
treatment. Change from baseline
in total fat mass: kg (a) and % (b);
total lean mass: kg (c) and % (d);
visceral fat mass: kg (e) and % (f);
ratio of total fat mass to total lean
mass (g); and cumulative change
in total fat mass (h). ‘On-
treatment without rescue
medication’ data ( n =114
[semaglutide, n = 53;
canagliflozin, n = 61]). Missing
data were multiple imputed using
observed data from participants
within the same group defined by
randomised treatment, using a
regressionmodel including region
as categorical effect and data from
baseline as covariate. (a–g)
Responses were analysed using
an ANCOVAwith treatment and
region as fixed factors and
baseline value as covariate.
Regions were defined as North
America (USA and Canada);
Region Europe (UK, Ireland and
Sweden); or International
Operations (Lebanon, Malaysia,
Argentina, Mexico, Brazil and
India). Numbers on the bars may
not match the numbers on the
scale due to rounding. (h) The
dashed line on the y-axis shows
the 50th percentile, while the
dashed line on the x-axis shows
the reference value for no change
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demonstrated greater reductions in fat mass (2.2 to 2.4 kg) vs
lean mass (1.1 to 1.2 kg) [37, 38]. These reductions occurred
in the context of a sustained elevation in spot urinary glucose
excretion, which is associated with decreased total body
weight and fat mass. Thus, the caloric loss from glucosuria,
and not fluid loss, was responsible for the reductions [38].
This is supported by results from a small study finding that
changes in extracellular water volume with SGLT-2is are tran-
sient, and not responsible for long-term weight loss with this
drug class [39].
Similar results were observed in trials assessing body
composition with other GLP-1RAs [32, 40, 41]. In a substudy
of the LEAD-2 trial, liraglutide 1.8 mg led to changes from
baseline in fat mass and lean mass of −2.4 kg and −1.5 kg,
respectively, over 26 weeks in 37 participants with type 2
diabetes [40]. In a separate prospective case-series study
investigating liraglutide in nine overweight or obese elderly
individuals with uncontrolled type 2 diabetes on metformin,
DXA demonstrated that mean fat mass was reduced by 1.5 kg,
but skeletal muscle index (a measure of muscle mass)
improved [41]. A second prospective case-series study
evaluated liraglutide 0.9 mg once daily in obese Japanese
individuals over 24 weeks [32]. In that study (n = 9), body
weight was reduced by 11.7%. Body composition analysis
from DXA scans showed that this was mostly caused by
decreases in visceral fat mass (mean reduction: 11.9%) and
intrahepatic lipid content (mean reduction: 49.2%) with no
change in subcutaneous fat. Fat mass index also decreased
(mean reduction: 10.9%) whereas skeletal muscle mass
remained unchanged [32]. While indirect comparisons across
clinical trials should be interpreted with caution, given the
heterogeneity of the study populations, these findings suggest
that body composition changes with semaglutide are consis-
tent with those in previous studies of other GLP-1RAs. These
changes are supported by the proposed mechanisms of weight
loss with GLP-1RAs through appetite modulation via the
central nervous system with minimal effect on energy expen-
diture [42, 43], as well as through the increase of natriuresis
caused by inhibition of the sodium–hydrogen ion transporter
in the proximal tubule, which subsequently reduces sodium
retention and extracellular fluid volume expansion [44]. An
additional mechanism may be nausea/vomiting, which was
a
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body weight (a), HbA1c (b), SBP (c) and DBP (d) after 52 weeks of treat-
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‘On-treatment without rescuemedication’ data for all randomised participants
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Table 2 Body composition
outcomes at week 52 (‘On-treat-
ment without rescue medication’
data)
Semaglutide
1.0 mg (n = 88)
Canagliflozin
300 mg (n = 90)
ETD (95% CI)
Total fat massa
Change at week 52, kg −3.41 (0.51) −2.62 (0.45) −0.79 (−2.10, 0.51)
Change at week 52, %-point −1.43 (0.39) −1.21 (0.35) −0.21 (−1.26, 0.84)
Total lean mass
Change at week 52, kg −2.26 (0.30) −1.48 (0.28) −0.78 (−1.61, 0.04)
Change at week 52, %-point 1.24 (0.39) 1.10 (0.34) 0.14 (−0.89, 1.17)
Total fat plus lean mass
(post hoc assessment)b
Change at week 52, kg −5.7 −4.1
Total fat mass:total lean mass, kg
Change at week 52 −0.04 (0.01) −0.03 (0.01) −0.01 (−0.04, 0.02)
Visceral fat mass
Change at week 52, kg −0.18 (0.05) −0.11 (0.04) −0.07 (−0.20, 0.06)
Change at week 52, %-point −0.94 (0.94) 0.44 (0.69) −1.38 (−3.65, 0.88)
Waist circumference, cm
Change at week 52c −3.9 (5.6) −2.5 (5.5)
Data are mean (SE) unless otherwise specified and represent estimates from an ANCOVAwith treatment, region
and baseline value as fixed effects
Multiple imputation was used where missing data were imputed using observed data from participants within the
same group defined by randomised treatment, using a regression model including region and stratification factor
as categorical effects and data from baseline and all previous visits as covariates
Regions were defined as North America (USA and Canada); Region Europe (UK, Ireland and Sweden); or
International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil and India)
a For total fat mass, responses were analysed with an ANCOVAwith treatment and region as fixed factors and
baseline value as covariate. Before analysis, missing data were multiple imputed using observed data from
participants within the same group defined by randomised treatment, using a regression model including region
as categorical effect and data from baseline as covariate
b Not pre-specified for the substudy; data are calculated as the sum of the estimated change (mean [SD])
c Not pre-specified for the substudy; data are mean (SD)
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Fig. 5 Proportion of participants achieving weight loss ≥3%, 5%, 10% or
15% of body weight from baseline after 52 weeks of treatment with
semaglutide 1.0 mg (a) and canagliflozin 300 mg (b) in SUSTAIN 8
(n = 788) and the SUSTAIN 8 substudy (n = 178). ‘On-treatment without
rescue medication’ data. Missing data were multiple imputed using
observed data from participants within the same group defined by
randomised treatment, using a regression model including region and
stratification factor as categorical effects and data from baseline and all
previous visits as covariates. Regions were defined as North America
(USA and Canada); Region Europe (UK, Ireland and Sweden); or
International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil
and India). This post hoc comparison of change in bodyweight within the
substudy vs the primary study was performed in order to confirm that
weight loss in participants undergoing a DXA scan in the substudy was
representative of the weight loss in the primary study
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shown to have a minimal effect on weight loss in a post hoc
mediation analysis of semaglutide vs exenatide extended
release and dulaglutide in the SUSTAIN 3 and 7 trials [45].
The positive effects of both treatments on weight loss
demonstrated previously [11–20, 24] highlight the impor-
tance of newer agents among current pharmacological
options, compared with older, standard approaches for type
2 diabetes that may increase or have little effect on weight
[46]. However, the greater reduction of weight loss with
semaglutide vs canagliflozin in the primary SUSTAIN 8
trial [17], when also taking into account the lack of statis-
tical difference in body composition changes between
treatments in this substudy, highlights the potential value
of semaglutide in terms of weight management in individ-
uals with uncontrolled type 2 diabetes on stable-dose
metformin therapy.
Strengths and weaknesses
The strengths of this substudy include the methods and design
of SUSTAIN 8, a double-blind randomised clinical trial with a
global population, relatively long treatment period of
52 weeks, and relevant head-to-head comparison with a
glucose-lowering medication with demonstrated efficacy in
type 2 diabetes. In addition, analysis and quality assessments
of the DXA scans were performed by one central imaging
laboratory using one brand of scanner, reducing the likelihood
of inconsistencies in bone and soft-tissue measurements that
can occur due to variability of hardware and software pack-
ages between DXA equipment manufacturers [47].
DXA is one of the most popular and widely used non-
invasive techniques for estimation of whole-body and regional
body composition [47–49]. However, body thickness and
hydration status can affect results [49], and lean muscle mass
may also include non-muscle components, such as blood or
interstitial fluid, leading to measurement error [50]. Moreover,
the inability of DXA to distinguish different types of fat
(visceral, subcutaneous, intramuscular) and lean soft tissues
(muscle, organs) represents a practical limitation [49]. The
lack of systematic collection of off-treatment DXA scans is a
weakness of this substudy. Some participants only received
baseline scans, and approximately a third did not have scans
available for the confirmatory analysis, mostly due to these
being taken out-of-window. However, results from the supple-
mentary in-trial analysis, which included all available data,
were similar to those observed in the confirmatory analysis
and confirm the robustness of data. Finally, the SUSTAIN 8
trial did not include a placebo arm, meaning that all changes in
body weight and composition reported here are comparisons
between active treatments, and it cannot be concluded that all
observed changes were entirely attributable to either
treatment.
Conclusion
In the SUSTAIN 8 substudy, the changes in body composition
between semaglutide and canagliflozin were not significantly
different in participants with uncontrolled type 2 diabetes on
stable-dose metformin therapy. Although numerical improve-
ments in body composition were observed following treat-
ment in both treatment arms, the specific impact of both treat-
ments on body composition in the absence of a placebo arm is
speculative at this stage.
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